Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 EraArticle Published on 2022-09-262022-11-15 Journal: Journal of Korean medical science [Category] 진단, [키워드] activity affected analyzed Annual calprotectin changed Characteristics Clinical characteristics coronavirus coronavirus disease COVID-19 COVID-19 pandemic Diagnosis disease enteral nutrition epidemiological Epidemiology fecal Including index Inflammatory bowel disease initial investigated Korean Last management multicenter multicenter study Occurrence outbreak outcome pandemic Patient pediatric pediatric. Phenotypes Research significant increase significantly significantly higher South Korea steroid Treatment treatment guideline trend ulcerative colitis Year [DOI] 10.3346/jkms.2022.37.e279 PMC 바로가기
C-reactive protein, immunothrombosis and venous thromboembolismArticle Published on 2022-09-132022-11-15 Journal: Frontiers in Immunology [Category] 바이오마커, [키워드] activating amplifying appear binding Biomarker C-reactive protein classical Clinical data Clinical practice clinical utility Complement pathway condition conserved COVID-19 CRP destabilized dissociate Effect elevated Elevation Evidence Features immunothrombosis Infection Inflammation Inflammatory bowel disease Inflammatory response isoform marker membrane monomeric Pathogenesis Platelet pro-inflammatory pro-thrombotic Prophylactic Protein raise required Sepsis subset therapeutic strategy Thromboinflammation thrombosis tissue damage triggering utility Venous Thromboembolism venous thromboembolism. VTE VTE risk with COVID-19 [DOI] 10.3389/fimmu.2022.1002652 PMC 바로가기
Misconceptions Drive COVID-19 Vaccine Hesistancy in Individuals with Inflammatory Bowel DiseaseArticle Published on 2022-09-102022-11-16 Journal: Canadian journal of gastroenterology & hepatology [Category] SARS, 변종, [키워드] 95% CI AOR Characteristics Complete concern COVID-19 COVID-19 vaccination COVID-19 vaccine demographic dose drive effective healthcare worker hospital IBD identify individual Infection Inflammatory bowel disease information Misconception more unwell National pandemic Patient patients Pregnancy public health measure Responder risk the SARS-CoV-2 unique vaccination Vaccine Vaccine hesitancy variable virus variant was used with COVID-19 [DOI] 10.1155/2022/4527844 PMC 바로가기
Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]Article Published on 2022-09-082022-11-15 Journal: Journal of Crohn's & colitis [Category] SARS, 진단, [키워드] Affect Against antagonists anti-SP IgG Anti-spike anti-TNF anti-tumour necrosis factor antagonists. Antibody Response booster vaccination bowel Cohort Complete COVID-19 COVID-19 vaccination determine Diagnosis diminished healthy control highlight IBD Immunoglobulin Impaired Inflammatory bowel disease inhibitor investigated medication mRNA vaccine Necrosis Patient Protein Quantitative receiving recruited response response to vaccination Result SARS-CoV-2 vaccination seroconvert seroconverted serological response significantly lower therapy TNF TNF antagonist Treatment vaccination vaccination against COVID-19 Vaccine vaccine response were assessed [DOI] 10.1093/ecco-jcc/jjac029 PMC 바로가기
Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease PatientsArticle Published on 2022-09-082022-11-15 Journal: Journal of Crohn's & colitis [Category] SARS, 진단, 치료기술, [키워드] analysed anti-nucleocapsid antibody anti-SARS-CoV-2 vaccine anti-spike antibody antibody baseline bowel cellular Cohort cohorts Concentration controls COVID-19 decrease functional humoral IBD individual Inflammatory Inflammatory bowel disease inhibitor Necrosis no difference nucleocapsid antigen Patient patients positive recipient released repeated response SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibody SARS-CoV-2-specific T-cell response Seven simple T-lymphocyte the healthy Treatment vaccinated individual vaccination vaccination. Vaccine vaccine dose vaccinee viral spike protein was performed were measured [DOI] 10.1093/ecco-jcc/jjac048 PMC 바로가기
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational studyObservational Study Published on 2022-09-022022-10-05 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adverse event Anaphylactic reaction antibody BNT162b2 combination therapy COVID-19 COVID-19 pandemic dose Efficacy and safety eligible patient evaluate evaluated event geometric group Health immunosuppressive indicated Inflammatory bowel disease Local majority MONITOR Patient patients Prospective prospective observational study SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination significant difference therapy treated U/mL vaccination vaccination against COVID-19 Vaccine vaccine administration [DOI] 10.1371/journal.pone.0273612 PMC 바로가기 [Article Type] Observational Study
SARS-CoV-2 Vaccine Response in Patients With Autoimmune HepatitisArticle Published on 2022-09-012022-11-15 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Autoimmune hepatitis China chronic liver disease Cohort coronavirus coronavirus disease death decrease disorder Europe glucocorticoid Hospitalization Immune-mediated Immunocompromised patients immunogenic inactivated incidence increased risk Inflammatory bowel disease Liver disease morbidity and mortality multicenter Patient provide reduce reduced response SARS-CoV-2 Serologic response shown the healthy vaccination vaccine-induced antibody variants of concern whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/j.cgh.2022.04.006 PMC 바로가기
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD PatientsArticle Published on 2022-08-242022-11-15 Journal: Canadian journal of gastroenterology & hepatology [Category] SARS, 진단, [키워드] addition age analysed association Cohort collected Course COVID-19 COVID-19 infection death died Evidence First wave Frame General population Germany hospital hotspot IBD ICU Immunoglobulin immunomodulator Immunotherapy Impact increased risk infection risk Inflammatory bowel disease inhibitor majority medication Munich occurred Older age Other Oxygen treatment Patient patients patients died positive Prevent problem protective role question receive reduced respiratory respiratory tract respiratory tract infection Respiratory tract infections SARS-CoV-2 SARS-COV-2 infection season severe COVID-19 significantly subject Support susceptible symptomatic tested the healthy therapy TNF tract Treatment Winter [DOI] 10.1155/2022/3469789 PMC 바로가기
Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study염증성 장질환이나 면역억제제는 심각한 COVID-19의 위험 증가와 관련이 없습니다: 관찰 네덜란드 코호트 연구Observational Study Published on 2022-08-012022-09-11 Journal: Clinical and experimental medicine [Category] SARS, 임상, 치료기술, [키워드] 95% confidence interval Admission affected Biological bowel Characteristics children clinical Cohort cohort characteristics cohort study Comorbidity COVID-19 COVID-19 case COVID-19 cases Crohn's disease Deceased determinant died disease examined Follow-up General population had no healthcare healthcare providers Hospital admission Hospitalized IBD ICD-10 Immunosuppressant immunosuppressants Immunotherapy increased risk Inflammatory bowel disease intensive care medication Mortality National observational study occurred Older outbreak Patient patients regions Respiratory Support Result retrospective risk factor Risk factors SARS-CoV-2 Seven severe COVID-19 significantly more the SARS-CoV-2 Thiopurine. Treatment was performed women [DOI] 10.1007/s10238-021-00755-3 PMC 바로가기 [Article Type] Observational Study
Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases급성 후 COVID-19는 염증성 장 질환에서 장 바이러스 항원 지속성을 특징으로 합니다Article Published on 2022-08-012022-09-11 Journal: Gastroenterology [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료법, [키워드] acute COVID-19 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected Antigen biochemical CD8 Chain Reaction clinical trials Confirmed COVID-19 infection controlled clinical trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Culture detectable endoscopy enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated expression of SARS-CoV-2 flow cytometry globe Gut gut mucosa IBD immune immune response immunofluorescence immunosuppressive immunosuppressive therapy Inflammation Inflammatory bowel disease intestine investigated large intestine majority means Mild nucleocapsid nucleocapsid protein pandemic Patient performed persistence polymerase chain polymerase chain reaction populations Postacute COVID-19 Quantitative quantitative polymerase chain reaction questionnaire reported RNA SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus severity Stool syndrome T cells therapy tissue Viral antigen Viral Antigen Persistence. viral nucleocapsid protein viral transcripts virus cultivation [DOI] 10.1053/j.gastro.2022.04.037 PMC 바로가기 [Article Type] Article